1803274-65-8

Basic information

• Product Name: BAY-1436032
• Synonyms: BAY-1436032
• CAS NO: 1803274-65-8
• Molecular Formula: C26H30F3N3O3
• Molecular Weight: 489.5299096
• Mol File: 1803274-65-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 591.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: BAY-1436032(CAS DataBase Reference)
• NIST Chemistry Reference: BAY-1436032(1803274-65-8)
• EPA Substance Registry System: BAY-1436032(1803274-65-8)

Safety Data

• Hazardous Substances Data: 1803274-65-8(Hazardous Substances Data)

Usage

Uses

BAY-1436032, is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

Upstream product

• 15901-42-5 (1R,5R)-3,3,5-trimethylcyclohexanamine 
• 907602-44-2 3-(4-fluoro-3-nitrophenyl)propionic acid methyl ester 
• 64285-95-6 1-isothiocyanato-4-(trifluoromethoxy)benzene 

Relevant articles and documents

FUSED IMIDAZOLES AS MIDH1 INHIBITORS

The present invention relates to compounds of general formula (I) : in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13/

METHOD FOR PREPARING SUBSTITUTED 3-(2-ANILINO-1-CYCLOHEXYL-1H-BENZIMIDAZOL-5-YL)PROPANOIC ACID DERIVATIVES

The present invention relates to a method for preparing substituted 3-(2-anilino-1-cyclohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives of the general formula (I) in which R1 represents a hydrogen atom or R1 represents a group selected from the series of C1-C3-alkyl-, C1-C3-alkoxy-, C1-C3-haloalkyl- and C1-C3-haloalkoxy-, R2 represents a hydrogen atom or a C1-C3-alkyl group, R3 represents a hydrogen atom or a C1-C3-alkyl group, R4 represents a cyclohexyl group, which is optionally singly or multiply substituted by a C1-C3-alkyl group, and R5 represents a hydrogen atom or a C1-C6-alkyl group; and also intermediates which may be used to prepare substituted 3-(2-anilino-1- cyclohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives. The present invention also relates to a crystalline form of 3-(2-{[4-(trifluoromethoxy)phenyl]amino}-1-[(1R,5R)-3,3,5- trimethylcyclohexyl]-1H-benzimidazol-5-yl)propanoic acid, pharmaceutical compositions comprising this crystalline form, and also the use of this crystalline form for preparing a medicament for the treatment of a disease.